I think CYP is fully recruited on the largest phase III iPSC stem cell trial of its kind in the world.
Some of you will recall JointStem out of Korea, who did a large phase III trial in autologous MSc cells on knee OA.
They go rejected in June last year by Korean authorities:
https://www.koreabiomed.com/news/articleView.html?idxno=21443
The market is wide open for CYP apart from one little known autologous application in the US (using patients own chondrocyte cells) but that all I know of - feel free to correct me, the usefulness of retail investors sharing information on Hot Copper - on the regenerative front before PAR holders tell me off.
I think we will all agree its a seriously ridiculous mkt cap for the Sculptor trial alone, let alone the various other potential commercial applications of Cymerus, and progress therein. Struggling non-profitable Bio-techs have of course been uniformly crushed in the silly Central Bank cycle (silly because they caused inflation with extended 2021 money pump as much as tight production supply - monetary economics 101) more than any other sector.
DFU (Sculptor?) initial indications coming to a screen near you soon. Rewards for the patient, and patients one hopes.
(20min delay)